Rhygaze
Basel
About Rhygaze
Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $97.3M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: rhygaze.com
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/rhygaze-88687 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.